Platform Overview
Nanomab is focusing on cancer precision therapies via the development of next generation radiopharmaceuticals.
The Company is developing medicines for fast and specific delivery of radiation to treat cancer. A therapeutic product is made by a camelid antibody labelled with a radioisotope of therapeutic radiation. This therapeutic product is paired with a diagnosic, using the same antibody vector but labelled with a lower radiation radioisotope for imaging. Its goal is to develop a pipeline of theranostic coupled camelid antibodies with its proprietary camelid antibodies platform to address the unmet medical need for cancer patients across the world.
Platform 1: Camelid sdAb:
Camelid single domain antibodies (sdAb) are the smallest naturally derived, single-domain, antigen-binding fragments. sdAb are obtained from a specific heavy-chain antibody (HcAb).
Camelid sdAb have many advantages over other commonly used vectors in radiopharmaceuticals both for diagnosis and treatment.
Platform 2: Theranostic: The use of highly selective theranostic coupled camelid sdAb for the diagnosis and treatment of cancer
The diagnostic camelid antibodies are radiolabelled with positron or gamma emitting radioisotopes and intravenously administered for whole-body imaging by SPECT or PET. The scan provides information on both primary and metastatic tumors, facilitating patient selection and drug response evaluation for cancer precision medicine. Diagnostic radioisotopes can be replaced with therapeutic radioisotopes suitable for molecular targeted radiation therapy, with the potential to provide novel treatment options for currently untreatable patients.
